Author Index

Ambrose, M.W., see Gilbert, B.E. (17) 33
Armstrong, J.A., see O'Marro, S.D. (17) 169
Asuncion, C., see O'Marro, S.D. (17) 169

Baba, M., Shigeta, S., Tanaka, H., Miyasaka, T., Ubasawa, M., Umezu, K., Walker, R.T., Pauwels, R., De Clercq, E., Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives (17) 245
Balzarini, J., see Perno, C.-F. (17) 289
Barnard, D.L., Huffman, J.H., Morris, J.L.B., Wood, S.G., Hughes, B.G., Sidwell, R.W., Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus (17) 63
Benson, J.D., see Huang, E.-S. (17) 17
Bergamini, A., see Perno, C.-F. (17) 289
Bradstreet, P., see Lebwohl, M. (17) 235
Burger, R.A., see Morrey, J.D. (17) 223

Calio, R., see Perno, C.-F. (17) 289
Chen, V., see Lebwohl, M. (17) 235
Cohen, J.S., see Kinchington, D. (17) 53
Conant, M., see Lebwohl, M. (17) 235
Connor, J., see Lebwohl, M. (17) 235

De Clercq, E., see Perno, C.-F. (17) 289
De Clercq, E., see Baba, M. (17) 245
Decker, R.S., see Volsky, D.J. (17) 335
Degols, G., Leonetti, J.-P., Milhaud, P., Mechti, N., Lebleu, B., Antisense inhibitors of HIV: problems and perspectives (17) 279
Devine, K.G., see McGuigan, C. (17) 311
Douglas Jr., J.M., see Lebwohl, M. (17) 235

Eron, L., see Lebwohl, M. (17) 235

Faras, A.J., see Ostrow, R.S. (17) 99
Fedorczyk, D., see Lebwohl, M. (17) 235
Forslund, K.M., see Ostrow, R.S. (17) 99
Fox, J.J., see Trousdale, M.D. (17) 157
Fraser-Smith, E.B., see Idowu, A.D. (17) 145

Galpin, S., see Kinchington, D. (17) 53
Gehrz, R.C., Nelson, C.M., Kari, B.E., A combination of human cytomegalovirus (HCMV)-specific murine monoclonal antibodies exhibit synergistic antiviral activity in vitro (17) 115
Ghosh, K., see Kinchington, D. (17) 53
Gilbert, B.E., Wyde, P.R., Ambrose, M.W., Wilson, S.Z., Knight, V., Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats (17) 33
Gueverra, L., see O'Marro, S.D. (17) 169

Hamblet, N., see Volsky, D.J. (17) 335
Hay, A.J., see McGuigan, C. (17) 311
Hayashi, K., Nishino, H., Niwayama, S., Shiraki, K., Hiramatsu, A., Yucca leaf protein (YLP) stops the protein synthesis in HSV-infected cells and inhibits virus replication (17) 323
Hayden, F.G., see Sperber, S.J. (17) 213
Herman, R.C., see Idowu, A.D. (17) 145
Herrmann, G., see Lin, J.-C. (17) 43
Hiramatsu, A., see Hayashi, K. (17) 323
Ho, M., see O'Marro, S.D. (17) 169
Huang, E.-S., Benson, J.D., Huong, S.-m., Wilson, B., van der Horst, C., Irreversible inhibition of human cytomegalovirus replication by topoisomerase II inhibitor, etoposide: a new strategy for the treatment of human cytomegalovirus infection (17) 17
Huffman, J.H., see Barnard, D.L. (17) 63
Huggins, J.W., see Ostrow, R.S. (17) 99
Hughes, B.G., see Barnard, D.L. (17) 63
Huong, S.-m., see Huang, E.-S. (17) 17
Idowu, A.D., Fraser-Smith, E.B., Poffenberger, K.L., Herman, R.C., Deletion of the herpes simplex virus type 1 ribonucleotide reductase gene alters virulence and latency in vivo (17) 145

Ijichi, K., see Machida, H. (17) 133

Jaroszewski, J.W., see Kinchington, D. (17) 53

Kari, B.E., see Gehrz, R.C. (17) 115
Kinchington, D., Galpin, S., Jaroszewski, J.W., Ghosh, K., Subasinghe, C., Cohen, J.S., A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1 (17) 53
Kinchington, D., see McGuigan, C. (17) 197
Knight, V., see Gilbert, B.E. (17) 33
Kumura, K., see Ochiai, H. (17) 1

Lamon, E.W., see Lidin, B. (17) 79
Law, J.L., see Trousdale, M.D. (17) 157
Lebleu, B., see Degols, G. (17) 279
Lebwohl, M., Sacks, S., Conant, M., Connor, J., Douglas Jr., J.M., Eron, L., Marlowe, S.,

Mendelson, J., Chen, V., Bradstreet, P., Fedorczyk, D., Trout, J.R., Plasse, T., Recombinant alpha-2 interferon gel treatment of recurrent herpes genitalis (17) 235
Leonetti, J.-P., see Degols, G. (17) 279
Li, G., see Volsky, D.J. (17) 335
Lidin, B., Lamon, E.W., Differential effects of human recombinant interferons on the expression of two early gene products of Epstein-Barr virus (17) 79
Lin, J.-C., Reefschläger, J., Herrmann, G., Pagano, J.S., Structure-activity relationship between (*E*)-5-(2-bromovinyl)- and 5-vinyl-1-β-D-arabinofuranosyluracil (BV-araU, V-araU) in inhibition of Epstein-Barr virus replication (17) 43
Lown, J.W., Lexitropsins in antiviral drug development (Mini-Review) (17) 179

Machida, H., Ijichi, K., Takezawa, J., Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice (17) 133
Mahmood, N., see McGuigan, C. (17) 311
Marlowe, S., see Lebwohl, M. (17) 235
Martin, J.A., Recent advances in the design of HIV proteinase inhibitors (17) 265
McGlennen, R.C., see Ostrow, R.S. (17) 99
McGuigan, C., Nickson, C., O'Connor, T.J., Kinchington, D., Synthesis and anti-HIV activity of some novel lactyl and glycolyl phosphate derivatives (17) 197
McGuigan, C., Pathirana, R.N., Mahmood, N., Devine, K.G., Hay, A.J., Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT (17) 311
Mead, J.R., see Morrey, J.D. (17) 223
Mechti, N., see Degols, G. (17) 279
Mendelson, J., see Lebwohl, M. (17) 235
Milanese, G., see Perno, C.-F. (17) 289
Milhaud, P., see Degols, G. (17) 279
Minamishima, Y., see Ochiai, H. (17) 1
Miyasaka, T., see Baba, M. (17) 245
Morrey, J.D., Mead, J.R., Warren, R.P., Okleberry, K.M., Burger, R.A., Sidwell, R.W., Elucidation of mode of retroviral-inhibitory effects of imexon through use of immune competent and severe combined immune deficiency (SCID) mice (17) 223
Morris, J.L.B., see Barnard, D.L. (17) 63

Nelson, C.M., see Gehrz, R.C. (17) 115
Nickson, C., see McGuigan, C. (17) 197
Nishino, H., see Hayashi, K. (17) 323
Niwayama, S., see Hayashi, K. (17) 323

O'Connor, T.J., see McGuigan, C. (17) 197
O'Marro, S.D., Armstrong, J.A., Asuncion, C., Gueverra, L., Ho, M., The effect of combinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro (17) 169
Ochiai, H., Kumura, K., Minamishima, Y., Murine cytomegalovirus DNA polymerase: purification, characterization and role in the antiviral activity of acyclovir (17) 1
Okleberry, K.M., see Morrey, J.D. (17) 223
Ostrow, R.S., Forslund, K.M., McGlennen, R.C., Shaw, D.P., Schlievert, P.M., Ussery, M.A., Huggins, J.W., Faras, A.J., Ribavirin mitigates wart growth in rabbits at early stages of infection with cottontail rabbit papillomavirus (17) 99

Pagano, J.S., see Lin, J.-C. (17) 43
Pathirana, R.N., see McGuigan, C. (17) 311
Pauwels, R., see Baba, M. (17) 245
Pauwels, R., see Perno, C.-F. (17) 289
Pellegrino, M.G., see Volsky, D.J. (17) 335
Perno, C.-F., Yarchoan, R., Balzarini, J., Bergamini, A., Milanese, G., Pauwels, R., De Clercq, E., Rocchi, G., Calio, R., Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages (17) 289
Plasse, T., see Lebwohl, M. (17) 235
Poffenberger, K.L., see Idowu, A.D. (17) 145
Potash, M.J., see Volsky, D.J. (17) 335

Reefschläger, J., see Lin, J.-C. (17) 43
Rocchi, G., see Perno, C.-F. (17) 289

Sacks, S., see Lebwohl, M. (17) 235
Schlievert, P.M., see Ostrow, R.S. (17) 99
Schooley, R.T., Challenges in the clinical development of antiretroviral drugs (17) 305
Shaw, D.P., see Ostrow, R.S. (17) 99
Shigeta, S., see Baba, M. (17) 245
Shiraki, K., see Hayashi, K. (17) 323
Sidwell, R.W., see Barnard, D.L. (17) 63
Sidwell, R.W., see Morrey, J.D. (17) 223
Smith, B.V., see Sperber, S.J. (17) 213
Sperber, S.J., Smith, B.V., Hayden, F.G., Serologic response and reactogenicity to booster immunization of healthy seropositive adults with live or inactivated varicella vaccine (17) 213
Subasinghe, C., see Kinchington, D. (17) 53

Takezawa, J., see Machida, H. (17) 133
Tanaka, H., see Baba, M. (17) 245
Trousdale, M.D., Law, J.L., Yarber, F.A., Watanabe, K.A., Fox, J.J., Evaluation of 1-(2'-deoxy-

2′-fluoro-β-D-arabinofuranosyl)-5-ethyluracil in a rabbit model of herpetic keratitis (17) 157
Trout, J.R., see Lebwohl, M. (17) 235

Ubasawa, M., see Baba, M. (17) 245
Umezu, K., see Baba, M. (17) 245
Ussery, M.A., see Ostrow, R.S. (17) 99

van der Horst, C., see Huang, E.-S. (17) 17
Volsky, B., see Volsky, D.J. (17) 335
Volsky, D.J., Li, G., Hamblet, N., Volsky, B., Decker, R.S., Pellegrino, M.G., Potash, M.J., Evaluation of multiple parameters of HIV-1 replication cycle in testing of AIDS drugs in vitro (17) 335

Walker, R.T., see Baba, M. (17) 245
Warren, R.P., see Morrey, J.D. (17) 223
Watanabe, K.A., see Trousdale, M.D. (17) 157
Wilson, B., see Huang, E.-S. (17) 17
Wilson, S.Z., see Gilbert, B.E. (17) 33
Wood, S.G., see Barnard, D.L. (17) 63
Wyde, P.R., see Gilbert, B.E. (17) 33

Yarber, F.A., see Trousdale, M.D. (17) 157
Yarchoan, R., see Perno, C.-F. (17) 289

Subject Index

ACV triphosphate; Murine cytomegalovirus (MCMV); DNA polymerase; Kinetic constant; Acyclovir (ACV) (17) 1
Acyclovir (ACV); ACV triphosphate; Murine cytomegalovirus (MCMV); DNA polymerase; Kinetic constant (17) 1
Aerosol; Respiratory syncytial virus; Influenza; Animal; Ribavirin (17) 33
AIDS; Antiviral; Drug resistance; Azidothymidine; Zidovudine; Dideoxyinosine; Human immunodeficiency virus (17) 169
AIDS; HIV; Friend virus; Severe combined immune deficient (SCID) mice; Biological response modifier (BRM); Imexon (17) 223
Animal; Ribavirin; Aerosol; Respiratory syncytial virus; Influenza (17) 33
Anthraquinone; Hypericin; Cytotoxicity; Virucidal; Human cytomegalovirus (17) 63
Anti-HIV drug; Cytokine; HIV; Macrophage; Lymphocyte (17) 289
Anti-HSV activity; Viral penetration; Protein synthesis inhibition; Yucca leaf protein (17) 323
Antigene; Antisense; Lexitropsin; Sequence selective; Drug development (17) 179
Antisense; Gag; HIV; Oligodeoxynucleotide; Phosphorothioate; Pol; Rev (17) 53
Antisense; Lexitropsin; Sequence selective; Drug development; Antigene (17) 179
Antiviral; Drug resistance; Azidothymidine; Zidovudine; Dideoxyinosine; Human immunodeficiency virus; AIDS (17) 169
Antiviral; Ocular disease; Herpesvirus; FEAU (17) 157
Azidothymidine; Zidovudine; Dideoxyinosine; Human immunodeficiency virus; AIDS; Antiviral; Drug resistance (17) 169
AZT; Nucleotide; Pro-drug; HIV (17) 311
AZT; Nucleotide; Pro-drug; Lactate; Glycolate; HIV (17) 197

Biological response modifier (BRM); Imexon; AIDS; HIV; Friend virus; Severe combined immune deficient (SCID) mice (17) 223
BV-araU; HSV-1; Mouse model; Skin infection; Immunocompromised (17) 133
BV-araU; V-araU; Epstein-Barr virus; EBV (17) 43

Chronic infection; Multiple parameter evaluation; Human immunodeficiency virus; Reverse transcriptase inhibitor (17) 335
Cytokine; HIV; Macrophage; Lymphocyte; Anti-HIV drug (17) 289
Cytotoxicity; Virucidal; Human cytomegalovirus; Anthraquinone; Hypericin (17) 63

Dideoxyinosine; Human immunodeficiency virus; AIDS; Antiviral; Drug resistance; Azidothymidine; Zidovudine (17) 169
DNA polymerase; Kinetic constant; Acyclovir (ACV); ACV triphosphate; Murine cytomegalovirus (MCMV) (17) 1
Drug development; Antigene; Antisense; Lexitropsin; Sequence selective (17) 179
Drug resistance; Azidothymidine; Zidovudine; Dideoxyinosine; Human immunodeficiency virus; AIDS; Antiviral (17) 169

EBV; BV-araU; V-araU; Epstein-Barr virus (17) 43
Enzyme inhibition; Transition-state analog; Peptide mimetic; HIV proteinase (17) 265
Epstein-Barr virus; EBV; BV-araU; V-araU (17) 43
Etoposide; Infection; Topoisomerase II; Human cytomegalovirus (17) 17

FEAU; Antiviral; Ocular disease; Herpesvirus (17) 157
Friend virus; Severe combined immune deficient (SCID) mice; Biological response modifier (BRM); Imexon; AIDS; HIV (17) 223

Gag; HIV; Oligodeoxynucleotide; Phosphorothioate; Pol; Rev; Antisense (17) 53
Glycolate; HIV; AZT; Nucleotide; Pro-drug; Lactate (17) 197

Herpes genitalis; Interferon; Topical (17) 235
Herpes simplex virus type 1; Virulence; Latency; Ribonucleotide reductase (17) 145
Herpesvirus; FEAU; Antiviral; Ocular disease (17) 157
HIV proteinase; Enzyme inhibition; Transition-state analog; Peptide mimetic (17) 265
HIV; AZT; Nucleotide; Pro-drug (17) 311
HIV; AZT; Nucleotide; Pro-drug; Lactate; Glycolate (17) 197
HIV; Friend virus; Severe combined immune deficient (SCID) mice; Biological response modifier (BRM); Imexon; AIDS (17) 223
HIV; Macrophage; Lymphocyte; Anti-HIV drug; Cytokine (17) 289
HIV; Oligodeoxynucleotide; Phosphorothioate; Pol; Rev; Antisense; Gag (17) 53

HIV-1 replication inhibition; 6-Phenylthiouracil derivative (17) 245
HSV-1; Mouse model; Skin infection; Immunocompromised; BV-araU (17) 133
Human cytomegalovirus, HCMV; Monoclonal antibody, HCMV-specific; Monoclonal antibody (17) 115
Human cytomegalovirus; Anthraquinone; Hypericin; Cytotoxicity; Virucidal (17) 63
Human cytomegalovirus; Etoposide; Infection; Topoisomerase II (17) 17
Human immunodeficiency virus; AIDS; Antiviral; Drug resistance; Azidothymidine; Zidovudine; Dideoxyinosine (17) 169
Human immunodeficiency virus; Reverse transcriptase inhibitor; Chronic infection; Multiple parameter evaluation (17) 335
Hypericin; Cytotoxicity; Virucidal; Human cytomegalovirus; Anthraquinone (17) 63

Imexon; AIDS; HIV; Friend virus; Severe combined immune deficient (SCID) mice; Biological response modifier (BRM) (17) 223
Immunocompromised; BV-araU; HSV-1; Mouse model; Skin infection (17) 133
Infection; Topoisomerase II; Human cytomegalovirus; Etoposide (17) 17
Influenza; Animal; Ribavirin; Aerosol; Respiratory syncytial virus (17) 33
Interferon; Topical; Herpes genitalis (17) 235

Kinetic constant; Acyclovir (ACV); ACV triphosphate; Murine cytomegalovirus (MCMV); DNA polymerase (17) 1

Lactate; Glycolate; HIV; AZT; Nucleotide; Prodrug (17) 197
Latency; Ribonucleotide reductase; Herpes simplex virus type 1; Virulence (17) 145
Lexitropsin; Sequence selective; Drug development; Antigene; Antisense (17) 179
Lymphocyte; Anti-HIV drug; Cytokine; HIV; Macrophage (17) 289

Macrophage; Lymphocyte; Anti-HIV drug; Cytokine; HIV (17) 289
Monoclonal antibody, HCMV-specific; Monoclonal antibody; Human cytomegalovirus, HCMV (17) 115
Monoclonal antibody; Human cytomegalovirus, HCMV; Monoclonal antibody, HCMV-specific (17) 115
Mouse model; Skin infection; Immunocompromised; BV-araU; HSV-1 (17) 133
Multiple parameter evaluation; Human immunodeficiency virus; Reverse transcriptase inhibitor; Chronic infection (17) 335
Murine cytomegalovirus (MCMV); DNA polymerase; Kinetic constant; Acyclovir (ACV); ACV triphosphate (17) 1

Nucleotide; Pro-drug; HIV; AZT (17) 311
Nucleotide; Pro-drug; Lactate; Glycolate; HIV; AZT (17) 197

Ocular disease; Herpesvirus; FEAU; Antiviral (17) 157
Oligodeoxynucleotide; Phosphorothioate; Pol; Rev; Antisense; Gag; HIV (17) 53

Papillomavirus; Ribavirin; Rabbit; Wart inhibition (17) 99
Peptide mimetic; HIV proteinase; Enzyme inhibition; Transition-state analog (17) 265
6-Phenylthiouracil derivative; HIV-1 replication inhibition (17) 245
Phosphorothioate; Pol; Rev; Antisense; Gag; HIV; Oligodeoxynucleotide (17) 53
Pol; Rev; Antisense; Gag; HIV; Oligodeoxynucleotide; Phosphorothioate (17) 53
Pro-drug; HIV; AZT; Nucleotide (17) 311
Pro-drug; Lactate; Glycolate; HIV; AZT; Nucleotide (17) 197
Protein synthesis inhibition; Yucca leaf protein; Anti-HSV activity; Viral penetration (17) 323

Rabbit; Wart inhibition; Papillomavirus; Ribavirin (17) 99
Respiratory syncytial virus; Influenza; Animal; Ribavirin; Aerosol (17) 33
Rev; Antisense; Gag; HIV; Oligodeoxynucleotide; Phosphorothioate; Pol (17) 53
Reverse transcriptase inhibitor; Chronic infection; Multiple parameter evaluation; Human immunodeficiency virus (17) 335
Ribavirin; Aerosol; Respiratory syncytial virus; Influenza; Animal (17) 33
Ribavirin; Rabbit; Wart inhibition; Papillomavirus (17) 99
Ribonucleotide reductase; Herpes simplex virus type 1; Virulence; Latency (17) 145

Sequence selective; Drug development; Antigene; Antisense; Lexitropsin (17) 179
Severe combined immune deficient (SCID) mice; Biological response modifier (BRM); Imexon; AIDS; HIV; Friend virus (17) 223
Skin infection; Immunocompromised; BV-araU; HSV-1; Mouse model (17) 133

Topical; Herpes genitalis; Interferon (17) 235
Topoisomerase II; Human cytomegalovirus; Etoposide; Infection (17) 17

Transition-state analog; Peptide mimetic; HIV proteinase; Enzyme inhibition (17) 265

V-araU; Epstein-Barr virus; EBV; BV-araU (17) 43
Viral penetration; Protein synthesis inhibition; Yucca leaf protein; Anti-HSV activity (17) 323
Virucidal; Human cytomegalovirus; Anthraquinone; Hypericin; Cytotoxicity (17) 63
Virulence; Latency; Ribonucleotide reductase; Herpes simplex virus type 1 (17) 145

Wart inhibition; Papillomavirus; Ribavirin; Rabbit (17) 99

Yucca leaf protein; Anti-HSV activity; Viral penetration; Protein synthesis inhibition (17) 323

Zidovudine; Dideoxyinosine; Human immunodeficiency virus; AIDS; Antiviral; Drug resistance; Azidothymidine (17) 169